Supriya Lifescience Limited share price

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it develops drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, an…Read more

Website NSE हिंदी में BSE

HealthcareBiotechnologyNifty Microcap 250NSE: SUPRIYAISIN INE07RO01027

16 Oct 2026, 3:29 PM IST₹886.00▲ 13.40 (1.54%)

Market Cap₹ 7,131 Cr.
Current Price₹ 886.00
High / Low₹ 1,085 / 546
Stock P/E35.9
Book Value₹ 149
Dividend Yield0.11 %
ROCE22.3 %
ROE19.10 %
Face Value₹ 2.0

More figures (10)

EPS (TTM)₹ 24.65
Price / Book5.96
OPM31.7 %
Debt / Equity0.00
Sales growth (3Y)21.6 %
Profit growth (3Y)32.5 %
Promoter holding71.3 %
EV / EBITDA24.4
Beta0.63
All-time high₹ 1,085

Price chart

Price on NSE 50 DMA 200 DMA Volume

Returns	1M	3M	6M	YTD	1Y	3Y CAGR	5Y CAGR
SUPRIYA	+0.93%	+4.16%	+41.02%	+17.90%	+22.60%	+53.91%	—
Nifty 50	-0.31%	-3.85%	-4.34%	-11.42%	-9.53%	+5.46%	+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

Supriya Lifescience Limited is in the Biotechnology industry (Healthcare), with a market value of ₹7,131 crore.
It trades at 35.9 times its last 12 months' earnings and 6.0 times book value.
Revenue grew 21.6% a year over the last 3 years, profit 32.5% a year.
Return on equity was 19.1% and return on capital employed 22.3% in the latest year.
Debt was 0.00 times shareholders' equity.
The share price is 18.3% below its 52-week high and up 22.6% over one year.
Promoters and insiders hold about 71.3%; institutions about 4.9%.

Pros

Strong return on equity: 18.5% on average over the last 3 years.
Company is almost debt-free (debt is 0.00 times equity).
Sales have grown 21.6% a year over the last 3 years.
Profit has grown 32.5% a year over the last 3 years.
Promoters hold a large stake of 68.30%.

Cons

Latest quarter (Jun 2026): profit fell 31% from a year ago.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Supriya Lifescience Limited

Employees: 607
Head office: Mumbai
NSE industry: Healthcare

HealthcareHealthcareBiotechnology

Part ofNifty Microcap 250

S.No.	Company	CMP ₹	P/E	Mar Cap ₹ Cr	Div Yld %	NP Qtr ₹ Cr	Qtr Profit Var %	Sales Qtr ₹ Cr	Qtr Sales Var %	ROCE %	ROE %	P/B	OPM %	Debt / Eq	Prom. Hold. %	Sales ₹ Cr	Sales Var 3Yrs %
1.	Supriya Lifescience	886.00	35.9	7,131	0.11	24	-30.89	190	30.79	22.3	19.1	5.96	31.7	0.00	71.28	828	21.6
2.	Biocon	349.20	103.3	57,190	0.14	137	53.36	4,336	10.00	2.8	1.4	1.66	10.3	0.45	48.12	16,927	15.3
3.	Anthem Biosciences	822.15	81.0	46,330	0.24	120	-11.67	418	-22.58	26.8	21.7	15.18	33.2	0.02	80.89	2,124	26.2
4.	OneSource Specialty Pharma	1,407.80	—	16,144	0.00	25	—	449	37.20	0.3	-1.3	2.77	-0.4	0.26	35.49	1,422	232.4
5.	Concord Biotech	1,339.00	46.1	14,008	0.56	58	30.96	257	26.23	16.7	13.6	6.94	29.1	0.00	72.48	1,046	8.0
6.	Blue Jet Healthcare	520.65	38.4	9,031	0.23	78	-28.91	293	-13.90	24.0	19.9	6.64	28.6	0.03	76.02	944	9.4
7.	Dishman Carbogen Amcis	149.83	146.9	2,349	0.00	-58	-347.24	678	-4.29	2.7	1.6	0.35	6.9	0.46	69.30	2,932	7.5
8.	Lyka Labs	87.79	—	317	0.00	2	105.44	42	28.11	-7.1	-10.2	3.39	-9.4	0.53	60.39	128	13.3
	Median: 8 Co.	671.40	63.6	11,520	0.13	41	-11.67	356	18.11	9.8	7.6	4.67	19.5	0.15	70.29	1,234	14.3

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Standalone figures in ₹ crore

₹ Cr	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	132	140	140	158	161	166	186	184	145	200	206	277	190
YOY Sales Growth %	30.26%	24.89%	33.23%	11.18%	21.67%	18.56%	32.54%	16.39%	-9.68%	20.31%	11.20%	50.20%	30.79%
	88	108	99	103	98	101	120	117	93	127	134	179	142
Material Cost %	36%	44%	39%	37%	30%	28%	33%	30%	22%	28%	30%	38%	30%
Employee Cost %	12%	12%	13%	11%	13%	12%	11%	11%	16%	12%	12%	9%	15%
Other Expenses %	19%	21%	19%	17%	18%	22%	21%	22%	27%	24%	23%	18%	30%
Operating Profit	44	32	41	56	63	65	66	68	52	73	72	98	47
OPM %	34%	23%	30%	35%	39%	39%	36%	37%	36%	36%	35%	35%	25%
	3	2	3	2	2	3	2	3	3	3	3	3	3
Exceptional items											-0
Interest	1	0	0	1	0	0	1	0	1	0	0	0	0
Depreciation	4	4	4	4	5	5	5	6	6	7	7	8	9
Profit before tax	43	30	40	53	60	62	63	64	47	68	67	92	41
	33%	20%	26%	31%	25%	26%	25%	21%	27%	26%	26%	19%	41%
Current tax	10	9	10	9	15	15	14	13	11	15	15	20	9
Deferred tax	4	-3	1	7	0	0	2	1	2	3	2	-3	8
	29	24	30	37	45	46	47	50	35	50	50	74	24
YOY Profit Growth %	12.92%	41.64%	212.96%	-3.39%	56.57%	93.22%	57.05%	36.42%	-22.07%	9.27%	6.18%	47.33%	-30.89%
EPS in Rs	3.54	2.97	3.70	4.59	5.54	5.71	5.82	6.29	4.32	6.27	6.17	9.22	2.99
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Standalone figures in ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	530	461	570	696	828	873
YOY Sales Growth %		-13.04%	23.74%	22.11%	18.86%
	316	332	397	436	534	583
Material Cost %	37%	39%	39%	30%	31%	32%
Employee Cost %	9%	12%	12%	12%	12%	12%
Other Expenses %	13%	21%	19%	21%	22%	23%
Operating Profit	214	129	173	261	294	290
OPM %	40%	28%	30%	37%	36%	33%
	8	9	11	10	11	11
Exceptional items					-0	-0
Interest	4	3	2	2	2	2
Depreciation	10	12	16	20	28	31
Profit before tax	207	123	166	248	275	268
	27%	27%	28%	24%	24%	26%
Current tax	52	31	37	57	61
Deferred tax	3	3	9	4	4
	152	90	119	188	209	198
YOY Profit Growth %		-40.81%	32.56%	57.80%	11.26%
EPS in Rs	18.86	11.16	14.80	23.35	25.98	24.65
Dividend Payout %		5%	4%	3%	4%

Compounded Sales Growth

3 Years:: 22%
TTM:: 28%

Compounded Profit Growth

3 Years:: 33%
TTM:: 11%

Stock Price CAGR

3 Years:: 54%
1 Year:: 23%

Return on Equity

4 Years:: 17%
Last Year:: 19%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	16	16	16	16
Reserves	683	799	981	1,182
	22	5	5	5
Short term borrowings	17
	98	101	115	154
Trade payables	64	60	75	111
Current liabilities	96	77	87	121
Total Liabilities	820	921	1,117	1,357
	328	457	609	723
Gross block	371	516	688	830
Accumulated depreciation	43	59	79	107
Goodwill & intangibles	1	2	1	1
CWIP	68	149	158	36
	425	315	350	598
Inventories	116	85	118	160
Trade receivables	85	112	134	219
Cash & equivalents	85	68	76	37
Current assets	465	398	442	532
Total Assets	820	921	1,117	1,357

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ Cr	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	64	113	165	186
Profit for the year	90	119	188	209
Working capital changes	-34	-17	-38	-47
Direct taxes paid	-31	-38	-59	-61
	-124	-174	-152	-176
Fixed assets purchased	-108	-146	-162	-152
Fixed assets sold	1
	-10	-22	-8	-10
Interest paid	-0	-1	-2	-2
Dividends paid	-5	-5	-6	-8
Net Cash Flow	-70	-83	4	-0
Free Cash Flow	-44	-32	2	34

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROE	—	12.8%	15.7%	20.7%	19.1%
ROCE	—	17.3%	20.1%	24.2%	22.3%
Operating margin	—	25.6%	28.3%	34.7%	31.7%
Net margin	—	19.9%	21.4%	27.7%	26.1%
Debt / equity	—	0.03	0.01	0.01	0.00
Current ratio	—	4.85	5.16	5.07	4.40
Debtor days	—	69	73	72	100
Inventory days	—	183	112	151	160
Days payable	—	102	78	95	111
Cash conversion cycle	—	150	107	128	149
Working capital days	—	299	210	191	187

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

Promoters 68.30%
FIIs 6.44%
DIIs 5.47%
Public 19.79%

%	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%	68.30%
	4.56%	5.36%	4.95%	6.03%	6.52%	7.19%	6.78%	5.46%	5.20%	5.16%	6.19%	6.44%
Foreign portfolio investors (Cat. I)	2.56%	3.35%	2.89%	3.61%	3.75%	4.53%	4.51%	2.92%	2.38%	1.88%	2.25%	2.39%
Foreign portfolio investors (Cat. II)	2.00%	2.02%	2.06%	2.42%	2.77%	2.66%	2.27%	2.54%	2.81%	3.28%	3.93%	4.06%
	5.39%	5.30%	5.48%	5.45%	4.92%	4.26%	4.86%	5.22%	5.01%	5.70%	5.30%	5.47%
Mutual funds	0.04%	0.05%	0.13%	0.62%	0.67%	0.66%	0.68%	0.68%	0.67%	1.33%	1.29%	1.28%
Insurance companies	3.81%	3.71%	3.82%	3.23%	2.49%	1.70%	2.33%	2.36%	2.32%	2.35%	2.40%	2.37%
Alternative investment funds	1.54%	1.54%	1.53%	1.60%	1.77%	1.90%	1.85%	2.18%	2.01%	2.02%	1.61%	1.82%
	21.76%	21.04%	21.27%	20.23%	20.26%	20.26%	20.06%	21.02%	21.50%	20.84%	20.21%	19.79%
Retail (up to ₹2 lakh)	16.74%	16.10%	16.07%		15.41%	15.52%	15.51%	15.77%	15.61%	15.23%	14.74%	14.18%
HNIs (above ₹2 lakh)	0.77%	0.96%	1.12%		0.86%	0.88%	0.89%	1.00%	1.05%	0.98%	1.24%	1.25%
NRIs	1.00%	1.13%	1.27%	1.12%	1.14%	1.20%	1.16%	1.18%	1.17%	1.13%	1.11%	1.04%
Bodies corporate	1.80%	1.84%	1.55%	1.90%	1.61%	1.50%	1.45%	1.80%	2.53%	2.53%	2.17%	2.53%
No. of Shareholders	95,929	87,980	89,621	85,328	89,394	91,051	91,928	87,912	85,099	81,161	82,082	78,561

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Mutual funds & institutions holding Supriya Lifescience

Holder (above 1%)	Stake
Aditya Birla Sun Life Insurance Company LimitedInsurance	2.16%

As named in the shareholding pattern for Sep 2026 filed with NSE; mutual funds together hold 1.28% of the company. Shareholders below 1% are not named in the filing.

Documents

Announcements

All announcements on NSE →

Annual reports

Credit ratings

Credit RatingSupriya Lifescience Limited has informed the Exchange about Credit Rating30-Dec-2025

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date: 4 Sep 2026
Latest quarter: 30 Jun 2026
Financial year end: 31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Open an account How it works

Latest news

In the news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Supriya Lifescience Limited

What is the share price of Supriya Lifescience Limited today?

Supriya Lifescience Limited (SUPRIYA) last traded at ₹886.00 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.

What is the market cap of Supriya Lifescience Limited?

About ₹7,131 crore at the latest price.

What is the P/E ratio of Supriya Lifescience Limited?

About 35.9 times its earnings over the last 12 months.

Is Supriya Lifescience Limited a good investment?

We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.

How can I buy Supriya Lifescience Limited shares?

You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.

Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).

Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Get in touch

We typically respond within 2 hours on business days.

Call us

CA Amit Kumar Jain+91 93522 44475 Arihant Jain+91 80056 49698 Poornima Jain+91 92525 44475

Email ussupport@plenitude.co.in

WhatsAppChat with an expert

Visit us5C, Laxmi Colony, Near Bohra Ji Ka Bagh, Opp. Laxmi Mandir Cinema, Tonk Road, Jaipur, Rajasthan 302015

Mon–Sat · 10:00 AM – 7:00 PM IST

In your free consultation

A health check of your current investments
A goal-based plan for retirement, education or a home
Ways to save tax that fit your situation
Clear next steps, with zero pressure to invest

2,000+Investors

₹250 Cr+Client assets

15+ yrsExperience

AMFI Registered Mutual Fund Distributor · ARN-130934

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

100% free
No obligation
Reply within 2 hours

First name *

Last name *

Email *

Phone *

+91

I'm interested in *

Best day for a call

Preferred time

How can we help? (optional)

Upload your portfolio (optional, get a free expert review)Attach your portfolio statement · PDF, Excel or CSV (e.g. CAS), max 10 MB

I consent to being contacted by Plenitude Connect about financial services. My data will be handled as per the Privacy Policy.

Join 2,000+ investors who plan with Plenitude

Your details are private and never shared.